9:30–10:00 am

Association of Autistic Spectrum Disorder and MMR Vaccine: A Systematic Review of Current Epidemiological Evidence

Kumanan Wilson, M.D., M.Sc., Division of Clinical Decision Making and Health Care, Toronto General Research Institute, Canada

10:00–10:30 am

Age at First Measles-Mumps-Rubella Vaccination in Children with Autism and School-Matched Control Subjects

Frank DeStefano, M.D., Centers for Disease Control and Prevention

10:30–10:45 am

Break

10:45–11:15 am

Exposure to Thimerosal-Containing Vaccines in U.K. Children and Autism

Dr. Elizabeth Miller, Head, Immunisation Division, Public Health Laboratory Service, Communicable Disease Surveillance Centre, London

11:15–11:45 am

Vaccine Safety Datalink Study: Autism Outcome

Robert L. Davis, M.D., M.P.H., University of Washington Group Health, Cooperative Departments of Pediatrics Center for Health Studies and Epidemiology

11:45–12:15 pm

Study of the Association Between Thimerosal-Containing Vaccine and Autism in Denmark

Anders Peter Hviid, M.Sc., Department of Epidemiology Research, State Serum Institute, Copenhagen, Denmark

12:15–12:45 pm

Autism and Thimerosal-Containing Vaccines: Analysis of the Vaccine Adverse Events Reporting System (VAERS)

Mark R. Geier, M.D., Ph.D., President, The Genetic Centers of America

David Geier, President of MedCon

12:45–1:45 pm

Lunch



The National Academies | 500 Fifth St. N.W. | Washington, D.C. 20001
Copyright © National Academy of Sciences. All rights reserved.
Terms of Use and Privacy Statement